MB Therapeutics Secures Approval for 3D Printed Medicine in France
Written with artificial intelligence.
MB Therapeutics, a French start-up, has received approval from the French National Agency for Medicines and Health Products Safety (ANSM) to manufacture semi-solid pharmaceutical cartridges for 3D printing solid oral dosage forms. This makes it the first facility globally authorized to produce such cartridges under official pharmaceutical standards.
Authorization and Impact
French start-up MB Therapeutics has been granted authorization by the French National Agency for Medicines and Health Products Safety (ANSM) to manufacture semi-solid pharmaceutical cartridges. These cartridges are intended for use in 3D printing solid oral dosage forms, marking a significant milestone as MB Therapeutics becomes the first site worldwide to receive this approval under official pharmaceutical manufacturer status.
Quality Control and Production
While the ANSM has approved the company’s application based on its quality management system and facilities, full production is yet to commence. The facility's operational compliance with Good Manufacturing Practices (GMP) is still underway, indicating that the company is in the final stages of meeting all regulatory requirements before launching its production.
Standardization for Personalization
The cartridges produced by MB Therapeutics will serve as standardized pharmaceutical products, prefilled in a GMP environment with a homogeneous paste containing active pharmaceutical ingredients (APIs) and excipients. This approach allows pharmacists to print oral medications at precise dosages tailored to individual patient needs, maintaining quality and traceability from cartridge production to the final dosage form.
Advancements in Personalized Medicine
The initiative aims to streamline personalized dosing by industrializing the formulation process, which typically occurs in hospital pharmacies. By providing standardized cartridges, the burden on pharmacists to manually compound medicines is reduced, allowing for greater accuracy and efficiency in patient care. Other companies, such as Finland’s CurifyLabs, are also pursuing similar methods to enhance pharmacy compounding through automation and standardized materials, contributing to the broader shift towards personalized medication practices.